Third Harmonic Bio Future Growth
Future criteria checks 0/6
Third Harmonic Bio's earnings are forecast to decline at 20.8% per annum. EPS is expected to decline by 13.4% per annum.
Key information
-20.8%
Earnings growth rate
-13.4%
EPS growth rate
| Pharmaceuticals earnings growth | 23.6% |
| Revenue growth rate | n/a |
| Future return on equity | -36.0% |
| Analyst coverage | Low |
| Last updated | 15 May 2024 |
Recent future growth updates
No updates
Recent updates
Here's Why We're Not At All Concerned With Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Situation
Apr 06
We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
Sep 06We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
May 02We're Not Very Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Rate
Dec 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -82 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -70 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -52 | N/A | N/A | 2 |
| 3/31/2024 | N/A | -30 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -31 | -21 | -20 | N/A |
| 9/30/2023 | N/A | -35 | -24 | -24 | N/A |
| 6/30/2023 | N/A | -36 | -31 | -31 | N/A |
| 3/31/2023 | N/A | -36 | -34 | -33 | N/A |
| 12/31/2022 | N/A | -35 | -35 | -35 | N/A |
| 9/30/2022 | N/A | -39 | -30 | -30 | N/A |
| 6/30/2022 | N/A | -39 | -23 | -23 | N/A |
| 3/31/2022 | N/A | -34 | -20 | -20 | N/A |
| 12/31/2021 | N/A | -30 | -16 | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: THRD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: THRD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: THRD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if THRD's revenue is forecast to grow faster than the US market.
High Growth Revenue: THRD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: THRD is forecast to be unprofitable in 3 years.